| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 3 | 0 | 9 | 5 | 4 | 5 | 4 | 5 | 6 | 5 | 5 | 6 | 5 | 6 | 8 | 8 | 4 | 3 | 6 | 9 | 9 | 5 | 13 | 16 | 16 | 16 | 19 | 21 | 17 | 11 | 8 | 10 | 8 | 11 | 8 | 10 | 11 | 13 | 12 | 13 | 10 | 9 | 13 |
| Expenses | 3 | 0 | 7 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 4 | 5 | 4 | 5 | 6 | 6 | 5 | 5 | 6 | 6 | 14 | 5 | 7 | 8 | 11 | 10 | 12 | 14 | 14 | 9 | 8 | 9 | 9 | 8 | 8 | 9 | 10 | 10 | 9 | 10 | 10 | 11 | 10 |
| EBITDA | 1 | 0 | 2 | 1 | -1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | -1 | -1 | 0 | 2 | -5 | 1 | 6 | 9 | 5 | 6 | 7 | 7 | 3 | 2 | -0 | 2 | -1 | 2 | 1 | 1 | 1 | 3 | 3 | 2 | -0 | -1 | 2 |
| Operating Profit % | 20 % | 0 % | 16 % | 19 % | -17 % | 16 % | 17 % | 17 % | 16 % | 9 % | 21 % | 21 % | 13 % | 22 % | 29 % | 32 % | -15 % | -42 % | -6 % | 23 % | -95 % | 15 % | 38 % | 53 % | 32 % | 36 % | 34 % | 32 % | -18 % | 12 % | -5 % | 15 % | -13 % | 20 % | 7 % | 10 % | 9 % | 25 % | 22 % | 17 % | -4 % | -20 % | 17 % |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Interest | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit Before Tax | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | -2 | -3 | -2 | 1 | -7 | -1 | 4 | 7 | 4 | 5 | 5 | 6 | 2 | 0 | -2 | 0 | -3 | 1 | -1 | -1 | -1 | 2 | 1 | 0 | -3 | -4 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | -0 | -1 | -0 | 0 | -1 | -0 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | -0 | -0 | 0 | -0 | 0 | -0 | -0 | 0 | 1 | 1 | 0 | -1 | -1 | 0 |
| Net Profit | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | -0 | 0 | 1 | 1 | -2 | -2 | -1 | 0 | -6 | -1 | 3 | 6 | 4 | 3 | 4 | 4 | 1 | 0 | -1 | 0 | -2 | 1 | -1 | -1 | -1 | 1 | 0 | 0 | -1 | -3 | 0 |
| EPS in ₹ | 0.70 | 0.00 | 1.50 | 0.25 | -1.77 | 0.16 | 0.20 | 0.24 | 0.51 | 0.03 | 0.09 | 0.12 | -0.05 | 0.26 | 0.93 | 0.52 | -0.97 | -1.37 | -0.95 | 0.26 | -3.56 | -0.37 | 1.79 | 3.74 | 2.56 | 2.17 | 2.45 | 2.80 | 0.52 | 0.25 | -0.78 | 0.04 | -1.51 | 0.33 | -0.39 | -0.31 | -0.47 | 0.66 | 0.16 | 0.03 | -0.81 | -2.03 | 0.01 |
Jeevan Scientific Technology
Jeevan Scientific Technology
62.47
+2.42
(4.03%)
Company has added their latest Financial Results15 hours ago
Show All
Key Fundamentals
Market Cap
95.00 Cr
EPS
-0.04
PE Ratio
-23.42
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
66.90
52 Week Low
32.85
PB Ratio
1.96
Debt to Equity
0.35
Sector
Healthcare Technology Actual
Company News
View All News
Jeevan Scientific Technology Limited held an Extraordinary General Meeting on November 12, 2025, through video conferencing from 10:00 AM to 10:40 AM. The meeting had 58 members in attendance out of 5,436 total shareholders on record date. All four proposed resolutions were passed with requisite majority: adoption of Memorandum of Association as per Companies Act 2013, increase in authorized share capital and consequent alteration of capital clause, issue of convertible warrants on preferential basis to promoters and non-promoters for cash consideration, and issue of equity shares on preferential basis to non-promoters for cash consideration. The voting was conducted through remote e-voting (November 9-11, 2025) and electronic voting during the meeting. AakankshaSachin Dubey served as the scrutinizer for the voting process.
Jeevan Scientific Technology Limited announced its unaudited financial results for the quarter and half year ended September 30, 2025. The Board of Directors approved both standalone and consolidated financial statements during their meeting held on November 12, 2025. The company's standalone cash flows show a net loss before tax of ₹268.56 lakhs for the half year ended September 30, 2025, compared to a profit of ₹77.05 lakhs for the year ended March 31, 2025. On a consolidated basis, the net loss before tax was ₹369.90 lakhs for the half year ended September 30, 2025, versus a profit of ₹5.07 lakhs for the year ended March 31, 2025. The consolidated results include subsidiary Nayas Laboratories Private Limited, which reported total revenues of ₹194.18 lakhs and net profit after tax of ₹9.50 lakhs for the quarter ended September 30, 2025.
Jeevan Scientific Technology Limited announced that the United States Food and Drug Administration (US FDA) completed a Remote Interactive Evaluation (RIE) of the company's Clinical Pharmacology facility from October 17, 2025 to November 6, 2025. The evaluation reviewed BA/BE studies as well as operations, systems and procedures. The RIE was completed successfully with no critical observations.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
663.85 | #1 25,985.60 | 57.11 | #1 3,714.20 | 3.77 | #1 496 | -36.76 | 58.07 | |
508.80 | 12,277.10 | 27.40 | 2,946.50 | 10.53 | 407 | 11.34 | 30.15 | |
188.02 | 4,149.60 | -20.19 | 17.60 | -46.34 | -161 | -55.85 | 41.06 | |
644.25 | 2,874.70 | 46.61 | 322.30 | 0.22 | 41 | 112.87 | 40.77 | |
26.16 | 368.70 | 7.96 | 10.20 | #1 126.67 | 1 | #1 493.75 | 73.51 | |
99.80 | 235.90 | -4.62 | 806.50 | 4.78 | -56 | 34.67 | 53.04 | |
62.47 | #7 95.00 | #1 -23.42 | #6 47.50 | #3 17.87 | #6 0 | #8 -100.00 | 63.66 | |
19.23 | 26.30 | 33.09 | 84.00 | 5.00 | 2 | -76.92 | 25.39 | |
26.22 | 18.60 | -1.40 | 2.10 | 40.00 | -13 | -566.67 | 20.38 |
Growth Rate
Revenue Growth
17.87 %
Net Income Growth
-107.69 %
Cash Flow Change
248.44 %
ROE
-104.40 %
ROCE
-353.70 %
EBITDA Margin (Avg.)
29.32 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 20 | 31 | 49 | 61 | 54 | 66 | 78 | 66 | 68 | 78 |
| Fixed Assets | 9 | 16 | 28 | 33 | 31 | 27 | 19 | 25 | 27 | 35 |
| Current Assets | 11 | 14 | 21 | 25 | 18 | 34 | 54 | 29 | 25 | 29 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 5 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 12 | 15 | 21 | 29 | 23 | 39 | 59 | 39 | 38 | 39 |
| Total Liabilities | 20 | 31 | 49 | 61 | 54 | 66 | 78 | 66 | 68 | 78 |
| Current Liabilities | 8 | 9 | 17 | 21 | 23 | 23 | 22 | 11 | 9 | 12 |
| Non Current Liabilities | 8 | 5 | 10 | 8 | 8 | 8 | 5 | 6 | 10 | 16 |
| Total Equity | 4 | 17 | 22 | 32 | 23 | 35 | 51 | 48 | 49 | 50 |
| Reserve & Surplus | -2 | 3 | 7 | 17 | 8 | 20 | 35 | 33 | 33 | 34 |
| Share Capital | 6 | 9 | 12 | 15 | 15 | 15 | 15 | 16 | 16 | 16 |
Cash Flow
| Cash Flow | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 0 | 1 | 2 | -2 | 4 | 24 | -23 | -6 | -0 |
| Investing Activities | -4 | -9 | -14 | -8 | -2 | -1 | -1 | -7 | -12 | -16 |
| Operating Activities | 4 | -6 | 6 | 4 | 0 | 5 | 20 | -6 | 3 | 10 |
| Financing Activities | 0 | 15 | 10 | 6 | 0 | -0 | 6 | -10 | 2 | 5 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 38.11 % | 38.11 % | 38.11 % | 38.11 % | 36.15 % | 36.47 % | 36.47 % | 36.85 % | 38.44 % | 38.48 % | 38.48 % | 38.48 % | 38.70 % | 38.70 % | 38.70 % | 37.84 % | 38.05 % | 38.05 % | 38.05 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 48.08 % | 45.99 % | 46.82 % | 46.70 % | 48.56 % | 48.38 % | 44.89 % | 44.65 % | 42.87 % | 42.89 % | 45.98 % | 45.51 % | 45.50 % | 45.34 % | 45.75 % | 45.91 % | 42.99 % | 42.75 % | 42.76 % |
| Others | 13.81 % | 15.90 % | 15.06 % | 15.18 % | 15.29 % | 15.15 % | 18.64 % | 18.50 % | 18.69 % | 18.63 % | 15.53 % | 16.00 % | 15.80 % | 15.96 % | 15.55 % | 16.25 % | 18.96 % | 19.21 % | 19.19 % |
| No of Share Holders | 2,740 | 3,999 | 5,499 | 5,813 | 6,144 | 6,439 | 6,449 | 6,295 | 6,061 | 5,911 | 5,933 | 5,727 | 5,749 | 5,655 | 5,607 | 5,565 | 5,497 | 5,460 | 5,444 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.5 | 1.2 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.38 | 2.38 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 12 Nov 2025 |  Quarterly Result Announcement | NA | 12 Nov 2025 | 62.83 | 60.05 |
| 12 Nov 2025 |  Extraordinary General Meeting | NA | 12 Nov 2025 | 55.77 | 60.05 |
| 08 Sept 2021 |  Dividend | ₹ 0.50 /share | 07 Sept 2021 | 98.10 | 96.40 |
| 23 Sept 2022 | Dividend | ₹ 1.20 /share | 21 Sept 2022 | 83.05 | 66.35 |
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 50.73 | 56.59 |
| 08 Nov 2024 | Quarterly Result Announcement | NA | 08 Nov 2024 | 52.94 | 52.88 |
| 06 Feb 2025 | Quarterly Result Announcement | NA | 06 Feb 2025 | 45.04 | 45.23 |
| 27 Mar 2025 | Extraordinary General Meeting | NA | 27 Mar 2025 | 43.01 | 41.38 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 41.03 | 40.32 |
| 14 Aug 2025 | Quarterly Result Announcement | NA | 14 Aug 2025 | 39.36 | 42.31 |
| 27 Sept 2025 | Annual General Meeting | NA | 27 Sept 2025 | 38.41 | 35.00 |
Announcements
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
12 hours ago
12 hours agoShareholder Meeting / Postal Ballot-Scrutinizer"s Report14 hours ago
14 hours agoShareholder Meeting / Postal Ballot-Outcome of EGM14 hours ago
14 hours agoUnaudited Financial Results For The Quarter And Half Year Ended 30.09.202515 hours ago
15 hours agoBoard Meeting Outcome for Outcome Of The Board Meeting Held On 12.11.202515 hours ago
15 hours agoBoard Meeting Intimation for Intimation Of Board Meeting To Be Held On 12.11.20255 days ago
5 days agoCorporate Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 About The Completion Of US FDA Remote Interactive Evaluation (RIE) Of JSTL.5 days ago
5 days agoExtra-Ordinary General Meeting Of The Company To Be Held On Wednesday 12Th Day Of November 2025 At 10.00 A.M. Through
Video Conference / Other Audio-Visual Means (VC/OAVM)Oct 18, 2025
Oct 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 15, 2025
Oct 15, 2025Announcement under Regulation 30 (LODR)-Preferential IssueOct 15, 2025
Oct 15, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 15.10.2025Oct 15, 2025
Oct 15, 2025Board Meeting Intimation for Prior Intimation Of Board Meeting For Consideration Of Fund-Raising ProposalOct 10, 2025
Oct 10, 2025Announcement under Regulation 30 (LODR)-RetirementOct 06, 2025
Oct 06, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 27, 2025
Sep 27, 2025Outcome Of 27Th Annual General Meeting Held On 27Th September2025.Sep 27, 2025
Sep 27, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Intimation Of Book Closure And Cut-Off Date For The 27Th Annual General Meeting Of Jeevan Scientific Technology Limited.Sep 05, 2025
Sep 05, 2025Annual General Meeting Of The Company Is Scheduled To Be Held On Saturday 27Th Day Of September 2025 At 10.00 A.M Through Video Conference VC / Other Audio-Visual Means.Sep 05, 2025
Sep 05, 2025Reg. 34 (1) Annual Report.Sep 05, 2025
Sep 05, 2025Reg. 34 (1) Annual Report.Sep 05, 2025
Sep 05, 2025Annual General Meeting Of The Company Is Scheduled To Be Held On Saturday 27Th Day Of September 2025 At 10.00 A.M Through Video Conference "VC" I Other Audio-Visual Means.Sep 05, 2025
Sep 05, 2025Announcement under Regulation 30 (LODR)-Resignation of DirectorAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 14, 2025
Aug 14, 2025Un Audited Financial Results For The Quarter Ended 30.06.2025Aug 14, 2025
Aug 14, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On 14.08.2025Aug 14, 2025
Aug 14, 2025Board Meeting Intimation for The Meeting To Be Held On 14.08.2025Aug 06, 2025
Aug 06, 2025Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 07.08.2025Aug 01, 2025
Aug 01, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 19, 2025
Jul 19, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2025
May 31, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 30, 2025
May 30, 2025Audited Results (Standalone And Consolidated) Of The Company For The Quarter And Year Ended 30.05.2025May 30, 2025
May 30, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On 30.05.2025May 30, 2025
May 30, 2025Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 30.05.2025May 26, 2025
May 26, 2025Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2Apr 30, 2025
Apr 30, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 30, 2025
Apr 30, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 15, 2025
Apr 15, 2025Information About Successful Completion Of Inspection Of JSTL Clinical And Bioanalytical Facilities By CDSCO (Central Drugs Standard Control Organisation) Under Regulation 30 Of SEBI (LODR) Regulations 2015.Apr 09, 2025
Apr 09, 2025Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 27, 2025
Mar 27, 2025Shareholder Meeting / Postal Ballot-Outcome of EGMMar 27, 2025
Mar 27, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 26, 2025
Mar 26, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 26, 2025
Mar 26, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 17, 2025
Mar 17, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 17, 2025
Mar 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 05, 2025
Mar 05, 2025Notice Of Extra-Ordinary General Meeting To Be Held On 27Th March 2025 At 10:00 AM.Mar 03, 2025
Mar 03, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On 01.03.2025Mar 01, 2025
Mar 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 08, 2025
Feb 08, 2025Technical Indicators
RSI(14)
Neutral 63.66
ATR(14)
Less Volatile 3.55
STOCH(9,6)
Neutral 46.83
STOCH RSI(14)
Oversold 8.22
MACD(12,26)
Bearish -0.96
ADX(14)
Strong Trend 40.73
UO(9)
Bearish 52.23
ROC(12)
Uptrend And Accelerating 3.84
WillR(14)
Neutral -45.67
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
